Amgen to Expand U.S. Manufacturing with $650M Investment
Amgen has announced a $650 million expansion of its U.S. manufacturing facilities, a development that will create almost 750 new positions. The expansion will...
US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly
Eli Lilly and Company has received U.S. Food and Drug Administration (FDA) approval for Inluriyo (imlunestrant, 200 mg tablets), an oral estrogen receptor antagonist....
Lilly to Build $6.5B API Manufacturing Facility in Houston
Eli Lilly and Company has unveiled plans for a $6.5 billion manufacturing facility in Generation Park, Houston, Texas. The project, described as a next-generation...
US FDA to Approve Leucovorin for Cerebral Folate Deficiency
The U.S. Food and Drug Administration (FDA) has started the process to approve leucovorin calcium tablets as a treatment for patients with cerebral folate...
Merck and Siemens to Accelerate AI Driven Drug Development
Merck and Siemens have expanded their collaboration by signing a new Memorandum of Understanding (MoU) aimed at advancing digital transformation in the life science...
ABPI Launches Manifesto to Advance Scottish Pharma Sector
The Association of the British Pharmaceutical Industry (ABPI) has released its manifesto for the Scottish Government, calling for political leaders to act now and...
FDA Grant Approval for Opzelura Cream for Pediatric Eczema
The U.S. Food and Drug Administration has granted approval to Incyte’s eczema cream, Opzelura, for use in children aged 2 to 11 years, the...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...